Need for inclusion of high-risk populations and standardisation of immunogenicity outcomes in adult pneumococcal vaccine trials. - Harboe ZB; Cordero E; Moran C; Kuijpers L; Epaulard O; Vollaard A (The Lancet. Infectious diseases, 2025)